RXRX
Recursion Pharmaceuticals, Inc. Class A · NASDAQ
- Sector Health Technology
- Industry Biotechnology
- Website recursion.com
- Employees(FY) 550
- ISIN US75629V1044
Performance
-1.58%
1W
+5.07%
1M
+21.9%
3M
-12.34%
6M
-24.34%
YTD
-1.32%
1Y
Profile
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 1b/2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer; REC-64151 for the treatment of immune checkpoint resistance; and Anti-PD-(L)1, an orally bioavailable small molecule to improve sensitivity to immune checkpoint inhibitors in non-small cell lung cancer and additional tumors. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Technical Analysis of RXRX 2024-12-10
Technical Scores and Rating
Moving Average Score
Oscillator Score
Technical Rating
Recent News & Updates
- 2024-12-10 05:03
- 2024-12-09 18:00
- 2024-12-09 05:00
- 2024-12-06 17:51
- 2024-12-04 14:01
- 2024-12-03 19:45
- 2024-12-03 08:30
- 2024-12-02 19:30
- 2024-11-27 13:20
- 2024-11-22 10:00
- 2024-11-20 08:50
- 2024-11-20 07:00
- 2024-11-19 18:00
- 2024-11-15 09:03
Nvidia Discloses Stake In Applied Digital, Keeps Arm, SoundHound Stakes(Investor's Business Daily)
- 2024-11-13 09:47
- 2024-11-13 09:08
- 2024-11-12 20:08
- 2024-11-12 16:54
- 2024-11-12 03:54
- 2024-11-10 08:42
- 2024-11-06 18:55
- 2024-11-06 17:57
Recursion Pharmaceuticals: Q3 Earnings Snapshot(Associated Press Finance)
- 2024-11-06 16:15
- 2024-11-05 07:45
- 2024-11-02 09:45
- 2024-11-01 17:45
- 2024-10-30 17:50
- 2024-10-30 08:22
- 2024-10-29 20:22
- 2024-10-25 21:00
Page 1 of 10
previousnext
Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.